Harris, T
Fat Metabolism Stimulates lipolysis , breaking down triglycerides in adipose tissue Reduces fat mass, especially visceral fat 3
Due to an inability of performing NMR-imaging on the required patients needed to adhere to the initial power calculation of the primary endpoint, liver fat, an amendment was added to the protocol allowing the inclusion of an additional 10 patients
Side-by-Side: DAC vs No-DAC | Side Effect | DAC | No-DAC | |---|---|---| | Flushing | Moderate | Mild | | Headache | Mild | Mild | | Water retention | Mild to moderate | Minimal | | Tingling | Reported more | Reported less | | Vivid dreams | Reported less | Reported more | | Insulin sensitivity over time | Higher theoretical concern | Lower | And for the record, here's what CJC-1295 does not typically cause at compounded doses: significant cortisol elevation, significant prolactin elevation, severe hunger spikes (that's GHRP-6's territory), mood changes, acute hypoglycemia, or acromegalic changes
Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad H, Grnbaek H, Tjnneland A, Halkjaer J, Dossus L, Boeing H, Krger J, Trichopoulou A, Dilis V, Trichopoulos D, Boutron-Ruault MC, De Lauzon B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Vrieling A, van Gils CH, Peeters PH, Gram IT, Skeie G, Lund E: The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition
